duloxetine HCl

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Stress Urinary Incontinence

Conditions

Stress Urinary Incontinence

Trial Timeline

Feb 1, 2004 → Jul 1, 2005

About duloxetine HCl

duloxetine HCl is a approved stage product being developed by Eli Lilly for Stress Urinary Incontinence. The current trial status is completed. This product is registered under clinical trial identifier NCT00190905. Target conditions include Stress Urinary Incontinence.

What happened to similar drugs?

5 of 20 similar drugs in Stress Urinary Incontinence were approved

Approved (5) Terminated (1) Active (15)
solifenacinAstellas PharmaApproved
🔄Duloxetine + PlaceboEli LillyPhase 3
🔄DuloxetineEli LillyPhase 3
🔄Duloxetine + PlaceboEli LillyPhase 3
🔄DuloxetineEli LillyPhase 3
🔄Duloxetine hydrochlorideEli LillyPhase 3
🔄DuloxetineEli LillyPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00190905ApprovedCompleted

Competing Products

20 competing products in Stress Urinary Incontinence

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
35
agenT-797MiNK TherapeuticsPhase 1
19
Thermal stress and performance without a pre-cooling protocolPetros PharmaceuticalsPre-clinical
16
solifenacinAstellas PharmaApproved
43
SivelestatEli LillyPhase 1/2
32
Duloxetine + PlaceboEli LillyPhase 3
40
DuloxetineEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
DuloxetineEli LillyPhase 3
40
Duloxetine hydrochlorideEli LillyPhase 3
36
DuloxetineEli LillyPhase 3
40
duloxetine + PlaceboEli LillyPhase 2
35
Exenatide + InsulinEli LillyPhase 2/3
38
DuloxetineEli LillyPhase 3
40
Orforglipron + PlaceboEli LillyPhase 3
47
Duloxetine hydrochloride + placeboEli LillyApproved
43
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine + placeboEli LillyPhase 3
40
DuloxetineEli LillyPhase 3
40
Duloxetine Hydrochloride + placeboEli LillyPhase 3
40